Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
life sciences & biomedicine (41) 41
science & technology (41) 41
female (30) 30
oncology (28) 28
biological and medical sciences (20) 20
medical sciences (20) 20
male (19) 19
chemotherapy (18) 18
tumors (17) 17
middle aged (15) 15
breast cancer (14) 14
cancer (14) 14
chemotherapy, adjuvant (13) 13
child (13) 13
liver cancer (13) 13
risk factors (13) 13
adolescent (12) 12
breast neoplasms - drug therapy (12) 12
child, preschool (12) 12
treatment outcome (12) 12
adult (11) 11
aged (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
clinical trials (11) 11
disease-free survival (11) 11
hepatoblastoma (11) 11
infant (11) 11
abridged index medicus (10) 10
hematology, oncology and palliative medicine (10) 10
research (10) 10
tamoxifen (10) 10
follow-up studies (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
cisplatin - administration & dosage (8) 8
doxorubicin - administration & dosage (8) 8
liver neoplasms - mortality (8) 8
liver neoplasms - pathology (8) 8
pharmacology. drug treatments (8) 8
prognosis (8) 8
survival (8) 8
610 medicine & health (7) 7
care and treatment (7) 7
hepatoblastoma - mortality (7) 7
hepatoblastoma - pathology (7) 7
hepatoblastoma - therapy (7) 7
infant, newborn (7) 7
patients (7) 7
prospective studies (7) 7
quality of life (7) 7
breast neoplasms - genetics (6) 6
combined modality therapy (6) 6
general & internal medicine (6) 6
health aspects (6) 6
liver (6) 6
liver neoplasms - drug therapy (6) 6
liver neoplasms - therapy (6) 6
medical colleges (6) 6
medicine, general & internal (6) 6
survival rate (6) 6
tamoxifen - therapeutic use (6) 6
antineoplastic agents (5) 5
antineoplastic agents, hormonal - therapeutic use (5) 5
aromatase inhibitors - therapeutic use (5) 5
breast neoplasms - surgery (5) 5
children (5) 5
diagnosis (5) 5
gastroenterology. liver. pancreas. abdomen (5) 5
hepatoblastoma - drug therapy (5) 5
kaplan-meier estimate (5) 5
liver neoplasms - surgery (5) 5
metastases (5) 5
pediatrics (5) 5
premenopause (5) 5
randomized controlled trials as topic (5) 5
survival analysis (5) 5
alpha-fetoproteins - metabolism (4) 4
analysis (4) 4
androstadienes - therapeutic use (4) 4
antineoplastic agents, hormonal - adverse effects (4) 4
breast neoplasms - mortality (4) 4
cancer therapies (4) 4
cisplatin (4) 4
contact allergy (4) 4
glycoproteins (4) 4
hematology (4) 4
hepatectomy (4) 4
hepatoblastoma - surgery (4) 4
international cooperation (4) 4
liver transplantation (4) 4
lung neoplasms - secondary (4) 4
medical research (4) 4
metastasis (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
surgery (4) 4
tamoxifen - adverse effects (4) 4
time factors (4) 4
age (3) 3
age factors (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
by Meyers, Rebecka L, Prof and Maibach, Rudolf, PhD and Hiyama, Eiso, Prof and Häberle, Beate, MD and Krailo, Mark, PhD and Rangaswami, Arun, Prof and Aronson, Daniel C, MD and Malogolowkin, Marcio H, Prof and Perilongo, Giorgio, Prof and von Schweinitz, Dietrich, Prof and Ansari, Marc, Prof and Lopez-Terrada, Dolores, Prof and Tanaka, Yukichi, MD and Alaggio, Rita, Prof and Leuschner, Ivo, Prof and Hishiki, Tomoro, MD and Schmid, Irene, MD and Watanabe, Kenichiro, MD and Yoshimura, Kenichi, PhD and Feng, Yurong, MSe and Rinaldi, Eugenia and Saraceno, Davide and Derosa, Marisa and Czauderna, Piotr, Prof
The lancet oncology, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 122 - 131
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Child, Preschool | Infant | Male | Liver Neoplasms - therapy | Neoplasm Staging - standards | Hepatoblastoma - secondary | Female | Liver Neoplasms - pathology | Child | Infant, Newborn | Databases, Factual | alpha-Fetoproteins - metabolism | Hepatoblastoma - therapy | Japan | Risk Factors | Cooperative Behavior | Survival Rate | Combined Modality Therapy | Lymphatic Metastasis | International Agencies | Adolescent | Pediatrics | Medical colleges | Liver cancer | International cooperation | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
by Zsiros, József, Dr and Brugieres, Laurence, MD and Brock, Penelope, MD and Roebuck, Derek, MD and Maibach, Rudolf, PhD and Zimmermann, Arthur, MD and Childs, Margaret and Pariente, Daniele, MD and Laithier, Veronique, MD and Otte, Jean-Bernard, Prof and Branchereau, Sophie, MD and Aronson, Daniel, MD and Rangaswami, Arun, MD and Ronghe, Milind, MD and Casanova, Michela, MD and Sullivan, Michael, MD and Morland, Bruce, MD and Czauderna, Piotr, MD and Perilongo, Giorgio, Prof and for the International Childhood Liver Tumours Strategy Group (SIOPEL) and Int Childhood Liver Tumours and International Childhood Liver Tumours Strategy Group (SIOPEL)
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 834 - 842
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Prospective Studies | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Child, Preschool | Male | Liver Neoplasms - therapy | Liver Neoplasms - mortality | Cisplatin - administration & dosage | Feasibility Studies | Hepatectomy | Dose-Response Relationship, Drug | Lung Neoplasms - secondary | Female | Liver Neoplasms - pathology | Child | Doxorubicin - administration & dosage | Hepatoblastoma - pathology | Hepatoblastoma - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Hepatoblastoma - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Antimitotic agents | Medical colleges | Liver cancer | Chemotherapy | Children's hospitals | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
by Pagani, Olivia and Regan, Meredith M and Walley, Barbara A and Fleming, Gini F and Colleoni, Marco and Láng, István and Gomez, Henry L and Tondini, Carlo and Burstein, Harold J and Perez, Edith A and Ciruelos, Eva and Stearns, Vered and Bonnefoi, Hervé R and Martino, Silvana and Geyer, Charles E and Pinotti, Graziella and Puglisi, Fabio and Crivellari, Diana and Ruhstaller, Thomas and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Bernhard, Jürg and Luo, Weixiu and Ribi, Karin and Viale, Giuseppe and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Francis, Prudence A and TEXT SOFT Investigators Int Breast and International Breast Cancer Study Group and TEXT and SOFT Investigators
The New England journal of medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | General aspects | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Estrogens | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
by Brock, Penelope R and Maibach, Rudolf and Childs, Margaret and Rajput, Kaukab and Roebuck, Derek and Sullivan, Michael J and Laithier, Véronique and Ronghe, Milind and Dall’Igna, Patrizia and Hiyama, Eiso and Brichard, Bénédicte and Skeen, Jane and Mateos, M. Elena and Capra, Michael and Rangaswami, Arun A and Ansari, Marc and Rechnitzer, Catherine and Veal, Gareth J and Covezzoli, Anna and Brugières, Laurence and Perilongo, Giorgio and Czauderna, Piotr and Morland, Bruce and Neuwelt, Edward A
The New England journal of medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2376 - 2385
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Thiosulfates - therapeutic use | Follow-Up Studies | Thiosulfates - adverse effects | Humans | Child, Preschool | Infant | Male | Hepatoblastoma - drug therapy | Liver Neoplasms - mortality | Cisplatin - administration & dosage | Incidence | Female | Drug Therapy, Combination | Child | Hearing Loss - chemically induced | Doxorubicin - administration & dosage | Glomerular Filtration Rate | Liver Neoplasms - drug therapy | Hepatoblastoma - mortality | Adolescent | Survival Analysis | Cisplatin - adverse effects | Thiosulfates - administration & dosage | Hearing Loss - prevention & control | Complications and side effects | Safety and security measures | Dosage and administration | Drug therapy | Sodium thiosulfate | Cisplatin | Risk factors | Hearing loss | Medical research | Liver diseases | Medical imaging | Hearing impairment | α-Fetoprotein | Cancer therapies | Survival | Children & youth | Metastases | Design | Chemotherapy | Sodium | Thiosulfate | Surgery | Children | Deoxyribonucleic acid--DNA | Ototoxicity | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study
by József Zsíros and Rudolf Maibach and Elizabeth Shafford and Laurence Brugieres and Penelope Brock and Piotr Czauderna and Derek Roebuck and Margaret Childs and Arthur Zimmermann and Veronique Laithier and Jean-Bernard Otte and Beatriz de Camargo and Gordon MacKinlay and Marcelo Scopinaro and Daniel Aronson and Jack Plaschkes and Giorgio Perilongo
Journal of clinical oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2584 - 2590
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | Medical sciences | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Other diseases. Semiology | Tumors | Prospective Studies | Humans | Risk Factors | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Child, Preschool | Infant | Liver Neoplasms - surgery | Male | Treatment Outcome | Hepatoblastoma - drug therapy | Preoperative Care | Cisplatin - administration & dosage | Hepatoblastoma - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Female | Chemotherapy, Adjuvant | Child | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma
by Perilongo, Giorgio and Maibach, Rudolf and Shafford, Elisabeth and Brugieres, Laurence and Brock, Penelope and Morland, Bruce and de Camargo, Beatriz and Zsiros, Jozsef and Roebuck, Derek and Zimmermann, Arthur and Aronson, Daniel and Childs, Margaret and Widing, Eva and Laithier, Veronique and Plaschkes, Jack and Pritchard, Jon and Scopinaro, Marcello and MacKinlay, Gordon and Czauderna, Piotr
The New England journal of medicine, ISSN 0028-4793, 10/2009, Volume 361, Issue 17, pp. 1662 - 1670
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Biological and medical sciences | General aspects | Medical sciences | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Other diseases. Semiology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Hepatoblastoma - drug therapy | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Female | Chemotherapy, Adjuvant | Child | Doxorubicin - administration & dosage | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Liver Neoplasms - surgery | Hepatoblastoma - mortality | Disease Progression | Hepatoblastoma - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Survival Analysis | Cisplatin - adverse effects | Doxorubicin - adverse effects | Liver cancer | Care and treatment | Usage | Comparative analysis | Health aspects | Cisplatin | Confidence intervals | Clinical trials | Tomography | Chemotherapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients
by Cairo, Stefano and Armengol, Carolina and Maibach, Rudolf and Häberle, Beate and Becker, Kristina and Carrillo-Reixach, Juan and Guettier, Catherine and Vokuhl, Christian and Schmid, Irene and Buendia, Marie-Annick and Branchereau, Sophie and von Schweinitz, Dietrich and Kappler, Roland
European journal of cancer (1990), ISSN 0959-8049, 12/2020, Volume 141, pp. 30 - 39
Biomarker | 16-Gene signature | Expression | Hepatoblastoma | Risk stratification | Hepatoblastoma - genetics | Liver Neoplasms - classification | Liver Neoplasms - genetics | Humans | Risk Factors | Child, Preschool | Infant | Male | Disease-Free Survival | Adolescent | Female | Liver Neoplasms - pathology | Biomarkers, Tumor - genetics | Hepatoblastoma - classification | Child | Infant, Newborn | Hepatoblastoma - pathology | Liver cancer | Chemotherapy | Patient outcomes | Liver | Oncology, Experimental | Research | Risk factors | Cancer | International cooperation | Risk groups | Fetuses | Biomarkers | Risk | Histology | Mutation | α-Fetoprotein | Risk management | Survival | Tumors | Metastases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research
by Arnaud D. Roth and Nicola Fazio and Roger Stupp and Stephen Falk and Jürg Bernhard and Piercarlo Saletti and Dieter Köberle and Markus M. Borner and Kaspar Rufibach and Rudolf Maibach and Martin Wernli and Martin Leslie and Robert Glynne-Jones and Lukas Widmer and Matthew Seymour and Filippo de Braud and Swiss Group for Clinical Cancer Research
Journal of clinical oncology, ISSN 0732-183X, 08/2007, Volume 25, Issue 22, pp. 3217 - 3223
Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Treatment Outcome | Epirubicin - administration & dosage | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Cisplatin - administration & dosage | Taxoids - administration & dosage | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Adult | Female | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report
by Aronson, Daniel C and Weeda, Víola B and Maibach, Rudolf and Czauderna, Piotr and Dall’Igna, Patrizia and de Ville de Goyet, Jean and Branchereau, Sophie and Perilongo, Giorgio and Brock, Penelope and Zsiros, Joszef and Semeraro, Michaela and Chardot, Christophe and Wildhaber, Barbara and Morland, Bruce and Brugières, Laurence and the Childhood Liver Tumour Strategy Group (SIOPEL) and Childhood Liver Tumour Strategy and Childhood Liver Tumour Strategy Group (SIOPEL)
European journal of cancer (1990), ISSN 0959-8049, 01/2019, Volume 106, pp. 126 - 132
Children | Partial liver resection | Outcome | Hepatoblastoma | Positive margin | yes | Life Sciences & Biomedicine | Oncology | Science & Technology | Age Factors | Humans | Child, Preschool | Infant | Male | Hepatectomy - mortality | Liver Neoplasms - mortality | Neoplasm, Residual | Time Factors | Female | Liver Neoplasms - pathology | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Child | Infant, Newborn | Hepatoblastoma - pathology | Risk Assessment | Europe | Hepatectomy - adverse effects | Risk Factors | Margins of Excision | Neoplasm Recurrence, Local | Liver Neoplasms - surgery | Clinical Trials as Topic | Hepatoblastoma - mortality | Hepatoblastoma - surgery | Progression-Free Survival | Adolescent | Liver cancer | Chemotherapy | Prognosis | Surgery | Liver | Glycoproteins | Tumors | Cancer | Risk groups | Health risks | Clinical trials | Risk | Patients | Survival | Cisplatin | Confidence intervals | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights